Patents Assigned to ChronoRX, LLC
-
Publication number: 20110104137Abstract: Dosage forms and methods of use are disclosed for a) adjuncts administered individually or simultaneously with HMg-CoA reductase inhibitors (statins) and/or selective phosphodiesterase 5 inhibitors or, b) the administration of a conjugate consisting of the adjuncts and an HMG-CoA reductase inhibitor and/or a selective phosphodiesterase 5 inhibitor. The invention is useful in the amelioration of side effects associated with HMG-CoA reductase inhibitors and will improve their effectiveness in diseases for which these are useful. The invention will also improve the effectiveness in the of selective phosphodiesterase 5 inhibitors in patients using these medications alone or in conjunction with statins, for the treatment of erectile dysfunction.Type: ApplicationFiled: April 19, 2010Publication date: May 5, 2011Applicant: ChronoRX LLC, an Alaska Limited Liability CompanyInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20090068264Abstract: Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL).Type: ApplicationFiled: November 10, 2008Publication date: March 12, 2009Applicant: ChronoRX LLCInventors: Kenneth T. Richardson, Don C. Pearson, John A. Edwards
-
Patent number: 7351715Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intraoellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-?-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.Type: GrantFiled: July 25, 2003Date of Patent: April 1, 2008Assignee: ChronoRx, LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20060194808Abstract: Dosage forms and methods of use are disclosed for: a) the simultaneous administration of tetrahydrobiopterin (BH4) or a derivative, homolog or precursor thereof and lipoic acid (LA), or dihydrolipoic acid (DHLA), or a derivative, homolog or salt thereof or, b) the administration of a conjugate consisting of tetrahydrobiopterin bis-lipoate (TBL).Type: ApplicationFiled: January 6, 2006Publication date: August 31, 2006Applicant: ChronoRX LLC, an Alaska Limited Liability CompanyInventors: Kenneth Richardson, Don Pearson, John Edwards
-
Publication number: 20060188492Abstract: Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide/endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents are tetrahydrobiopterin, R-alpha-lipoic acid, coenzyme Q10, 17 alpha-estradiol, and glutathione.Type: ApplicationFiled: January 13, 2006Publication date: August 24, 2006Applicant: ChronoRX LLC, an Alaska Limited Liability CompanyInventors: Kenneth Richardson, Don Pearson
-
Patent number: 7060295Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.Type: GrantFiled: July 30, 2003Date of Patent: June 13, 2006Assignee: ChronoRX LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20040034030Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.Type: ApplicationFiled: July 30, 2003Publication date: February 19, 2004Applicant: ChronoRX LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Patent number: 6689385Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.Type: GrantFiled: November 2, 2001Date of Patent: February 10, 2004Assignee: Chronorx LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20040018996Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intraoellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-&agr;-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.Type: ApplicationFiled: July 25, 2003Publication date: January 29, 2004Applicant: ChronoRx, LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Patent number: 6632445Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-&agr;-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.Type: GrantFiled: July 30, 2002Date of Patent: October 14, 2003Assignee: ChronoRX, LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20030077335Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.Type: ApplicationFiled: November 2, 2001Publication date: April 24, 2003Applicant: ChronoRX LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20030078269Abstract: The invention describes formulations that include either metformin, sulfonylurea or a biguanide-sulfonylurea combination as one active ingredient in addition to specific, other active ingredients. The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of the included biguanide (metformin) and/or sulfonylurea in the prevention and treatment of insulin resistance and diabetes mellitus. The carefully chosen additional active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and those adverse incidences associated with the concurrent use of metformin and/or the sulfonylureas. When clinically administered, the invention will provide therapeutic levels of metformin and of a sulfonylurea, alone or in combination, and broaden their usefulness.Type: ApplicationFiled: March 7, 2002Publication date: April 24, 2003Applicant: ChronoRX, LLCInventors: Don C. Pearson, Kenneth T. Richardson
-
Patent number: 6531608Abstract: This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.Type: GrantFiled: June 11, 2002Date of Patent: March 11, 2003Assignee: Chronorx, LLC.Inventors: Don C. Pearson, Kenneth T. Richardson
-
Publication number: 20020197313Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-&agr;-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.Type: ApplicationFiled: July 30, 2002Publication date: December 26, 2002Applicant: ChronoRX, LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Publication number: 20020151533Abstract: This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.Type: ApplicationFiled: June 11, 2002Publication date: October 17, 2002Applicant: CHRONORX, LLC.Inventors: Don C. Pearson, Kenneth T. Richardson
-
Patent number: 6455061Abstract: The components of this invention are chosen because of their complementarity for the prevention or treatment of diseases caused by the herpes simplex virus. L-Lysine favorably increases the physiologic immunomodulation necessary for defense against this virus. Zinc improves and maintains a normal immune response. 2-Deoxy-2-D-glucose and heparin sodium alter the surface interaction between the herpes virus and the cell, preventing fusion and infectivity. N-Acetyl-L-cysteine increases glutathione levels thereby creating a thiol redox barrier to the virus at the cell membrane. Quercetin reduces intracellular replication of the herpes virus and viral infectivity. Ascorbate, in concert with copper and D-&agr;-tocopherol, provides an antioxidant defense against the herpes virus, which tends to lose latency during period of oxidative, free radical excess. Selenium and quercetin also participate in reducing various oxidative stresses.Type: GrantFiled: April 5, 2001Date of Patent: September 24, 2002Assignee: ChronoRX, LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Patent number: 6429219Abstract: This invention relates to the synthesis of certain complexes of cysteine, N-acetylcysteine, N-(2-mercaptopropionyl)glycine, and L-2-oxothiazolidine-4-carboxylate and to the nutritional use of these and other related individual or complexed thiol-contributing glutathione predecessors. Clinical uses for these molecules and complexes in the beneficial modification of various physiological conditions and functions associated with aging, chronic glaucoma, diabetes mellitus, insulin resistance, macular degeneration, neurodegenerative diseases and vasoconstriction are described in particular.Type: GrantFiled: May 3, 2000Date of Patent: August 6, 2002Assignee: Chronorx, LLCInventors: Don C. Pearson, Kenneth T. Richardson
-
Patent number: 6423847Abstract: A process of synthesis of D,&agr;-tocopherol nicotinate compounds is presented. Therapeutic uses for this compound are described. The active agents are demonstrated to be complementary in their physiological functions especially as these relate to cellular and endothelial biochemistry and physiology and, ultimately to vascular health. The active components of the invention are selected for inclusion in a unique combination that clinically reduces risks of vasculopathy, DNA strand breakage and neuronal excitotoxicity in various diseases. In addition to the systemic vascular benefits acquired, improvement of the vascular health of the eye reduces the risk of glaucomatous optic nerve atrophy with its accompanying visual field loss and potential blindness and reduces conditions of risk for macular degeneration.Type: GrantFiled: March 20, 2000Date of Patent: July 23, 2002Assignee: Chronorx, LLCInventors: Don C. Pearson, Kenneth T. Richardson
-
Patent number: 6359007Abstract: Various clinical uses for L-arginine complexes are presented. The active agents have individual and complementary physiological functions especially as these relate to conditions and functions, which influence endothelial biochemistry and physiology. The active components of the invention are selected for inclusion in unique combinations that will clinically reduce risks of vasculopathy in various diseases. The reduction of endothelial dysfunctional risks, often associated with aging and generalized poor vascular health and function, will maximize the potential clinical therapeutic success of other mediations and concurrently avoid some risks of pharmaceutical side effects.Type: GrantFiled: March 23, 2000Date of Patent: March 19, 2002Assignee: ChronoRX, LLCInventors: Don C. Pearson, Kenneth T. Richardson
-
Patent number: 6288106Abstract: This invention is in the fields of pharmacology and biochemistry. It relates to processes for the synthesis of certain complexes of &agr;-lipoic acid and the nutritional or therapeutic use of these and other related individual or complexed antioxidant, proglutathione molecules. Therapeutic uses for these molecules and complexes in the clinical management of conditions and functions associated with chronic glaucoma, insulin resistance, macular degeneration, lenticular cataract, neurodegenerative diseases, essential hypertension, atherosclerosis and vasoconstriction are described in particular.Type: GrantFiled: May 3, 2000Date of Patent: September 11, 2001Assignee: ChronoRX, LLCInventors: Don C. Pearson, Kenneth T. Richardson